Brief: Precision BioSciences Announces MHRA Approval For Partner iECURE To Expand Phase 1/2 Clinical Trial Of ARCUS Gene Editing Program In OTC Deficiency
06/03/2024 13:49
March 6 (Reuters) - Precision BioSciences Inc DTIL.O :
* PRECISION BIOSCIENCES ANNOUNCES MHRA APPROVAL FOR PARTNER
IECURE
TO EXPAND PHASE 1/2 CLINICAL TRIAL OF ARCUS GENE EDITING PROGRAM
IN OTC DEFICIENCY
Source text for Eikon: ID:nBw9fGVPqa
Further company coverage: DTIL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Precision Biosciences
See all newsPrecision BioSciences Inc reports results for the quarter ended June 30 - Earnings Summary
Precision BioSciences Q2 net loss widens on warrant liability charge
Precision BioSciences Inc expected to post a loss of 79 cents a share - Earnings Preview
Precision BioSciences Inc expected to post a loss of 79 cents a share - Earnings Preview
Brief: Precision Biosciences - Enters First Amendment To Loan And Security Agreement With Banc Of California - SEC Filing